The Congestive Heart Failure market growth is driven by factors like increase in the prevalence of Congestive Heart Failure, investments in research and development, entry of emerging therapies during the study period 2020-2034.
The Congestive Heart Failure market report [https://www.delveinsight.com/report-store/congestive-heart-failure-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr] also offers comprehensive insights into the Congestive Heart Failure market size, share, Congestive Heart Failure epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Congestive Heart Failure market size growth forward.
Some of the key highlights from the Congestive Heart Failure Market Insights Report:
*
Several key pharmaceutical companies, including Novartis, Boehringer Ingelheim, Eli Lilly, Bayer, Merck, AstraZeneca, Amgen, Otsuka Pharmaceutical, Cytokinetics, Mesoblast, Novo Nordisk, Lexicon Pharmaceuticals, scPharmaceuticals, Bristol-Myers Squibb, Intra-Cellular Therapies, Tenax Therapeutics, BioCardia, and others, are developing novel products to improve the Congestive Heart Failure treatment outlook.
*
In March 2024, the FDA granted a label expansion for Novo Nordisk’s Wegovy (semaglutide) to help reduce the risk of cardiovascular death, heart attack, and stroke in adults with cardiovascular disease and obesity or overweight. This approval was supported by data from the Phase III SELECT trial, which demonstrated that a 2.4 mg injection of Wegovy resulted in a 20% reduction in major adverse cardiovascular events compared to a placebo, when used alongside standard care.
*
In December 2024, Gerresheimer revealed that the FDA had given tentative approval to SQ Innovation for Lasix ONYU, a treatment for fluid overload in congestive heart failure to be administered at home.
*
In 2023, the total market size for Congestive Heart Failure (Congestive Heart Failure) in the 7MM was approximately USD 6,900 million, with the growing prevalence of the disease expected to drive market expansion during the forecast period from 2024 to 2034. According to the 2023 Heart Disease and Stroke Statistics report, the prevalence of heart failure is increasing due to factors such as an aging population, improved treatment and survival rates for ischemic heart disease, and the availability of effective therapies that extend the lives of heart failure patients.
*
The United States accounted for the highest number of prevalent heart failure cases among the 7MM in 2023.
*
Off-label therapies and generics dominate the current Congestive Heart Failure market due to their affordability and easy accessibility for patients. Generic versions of medications such as olmesartan, eplerenone, furosemide, and candesartan cilexetil are widely available, creating significant competition for newly developed drugs and hindering market growth.
*
Key players like AstraZeneca (FORXIGA), Novartis (ENTRESTO), Eli Lilly, and Boehringer Ingelheim (JARDIANCE) are increasingly focusing on label expansions and gaining approvals for treatments that can be used across a broader patient population, which is expected to drive the Congestive Heart Failure drug market forward.
*
The FDA approval of FUROSCIX represents a significant breakthrough in heart failure treatment, enabling certain patients to avoid costly hospitalizations by self-administering treatment at home, thus offering considerable cost savings without compromising patient well-being. This innovation is likely to be highly attractive to healthcare providers.
*
As per DelveInsight analysis, the Congestive Heart Failure market is anticipated to witness growth at a considerable CAGR.
Strategise your business goals by understanding market dynamics @ Congestive Heart Failure Market Landscape [https://www.delveinsight.com/sample-request/congestive-heart-failure-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Congestive Heart Failure Overview
Congestive Heart Failure (Congestive Heart Failure), also known as heart failure, is a chronic, progressive condition where the heart is unable to produce a cardiac output that meets the body’s demands without increasing diastolic pressure, often due to cardiac diseases that affect either the systolic or diastolic function of the ventricles. Heart failure is typically classified based on left ventricular ejection fraction (LVEF). Heart failure with a normal LVEF ( greater than or equal to 50%) is referred to as heart failure with preserved ejection fraction, while heart failure with reduced LVEF (
This release was published on openPR.
